Mast Therapeutics, Inc. (MSTX)

[RNsidersbuying]

Exact wording:

On June 6, 2016, Mast Therapeutics, Inc. (the “Company”) updated the anticipated timing for announcement of top-line data from the Company’s Phase 3 clinical study of vepoloxamer in patients with sickle cell disease, known as the EPIC study. The Company currently expects to complete database lock in July and report top-line data shortly thereafter. The delay does not reflect on the quality or integrity of the results or conduct of the study. Rather, validation of the multitude of data points generated by the study and quality assurance/quality control procedures have taken longer than previously anticipated.

How does one define "shortly thereafter"? Another several months perhaps and after another secondary and reverse-split lol?

Still alot of play in this one - even if they miss and the pps get's whacked 50% or so, this will be upcoming:

Our 150-patient Phase 2 study of vepoloxamer in chronic heart failure is ongoing, with ten study sites now open, and the HFN’s 100-patient Phase 2 study of AIR001 in HFpEF is expected to begin in the third quarter of 2016.”

Glass FULL scenario - what if they hit on EPIC and conduct the AIR001 HFpEF study in tandem - beautiful dreamer